Teams led by scientists from the Scripps Research Institute and the Seattle Biomedical Research Institute reported last week that they have engineered and identified, respectively, parts of HIV that can strongly stimulate naïve B cells to produce the sorts of antibodies that can ultimately become broadly effective against HIV – a step toward the development of an HIV vaccine that has long eluded researchers.